Germline Mutations in ATM and BRCA1/2 Distinguish Risk for Lethal and Indolent Prostate Cancer and are Associated with Early Age at Death.

Journal Article (Journal Article)

BACKGROUND: Germline mutations in BRCA1/2 and ATM have been associated with prostate cancer (PCa) risk. OBJECTIVE: To directly assess whether germline mutations in these three genes distinguish lethal from indolent PCa and whether they confer any effect on age at death. DESIGN, SETTING, AND PARTICIPANTS: A retrospective case-case study of 313 patients who died of PCa and 486 patients with low-risk localized PCa of European, African, and Chinese descent. Germline DNA of each of the 799 patients was sequenced for these three genes. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSIS: Mutation carrier rates and their effect on lethal PCa were analyzed using the Fisher's exact test and Cox regression analysis, respectively. RESULTS AND LIMITATIONS: The combined BRCA1/2 and ATM mutation carrier rate was significantly higher in lethal PCa patients (6.07%) than localized PCa patients (1.44%), p=0.0007. The rate also differed significantly among lethal PCa patients as a function of age at death (10.00%, 9.08%, 8.33%, 4.94%, and 2.97% in patients who died ≤ 60 yr, 61-65 yr, 66-70 yr, 71-75 yr, and over 75 yr, respectively, p=0.046) and time to death after diagnosis (12.26%, 4.76%, and 0.98% in patients who died ≤ 5 yr, 6-10 yr, and>10 yr after a PCa diagnosis, respectively, p=0.0006). Survival analysis in the entire cohort revealed mutation carriers remained an independent predictor of lethal PCa after adjusting for race and age, prostate-specific antigen, and Gleason score at the time of diagnosis (hazard ratio=2.13, 95% confidence interval: 1.24-3.66, p=0.004). A limitation of this study is that other DNA repair genes were not analyzed. CONCLUSIONS: Mutation status of BRCA1/2 and ATM distinguishes risk for lethal and indolent PCa and is associated with earlier age at death and shorter survival time. PATIENT SUMMARY: Prostate cancer patients with inherited mutations in BRCA1/2 and ATM are more likely to die of prostate cancer and do so at an earlier age.

Full Text

Duke Authors

Cited Authors

  • Na, R; Zheng, SL; Han, M; Yu, H; Jiang, D; Shah, S; Ewing, CM; Zhang, L; Novakovic, K; Petkewicz, J; Gulukota, K; Helseth, DL; Quinn, M; Humphries, E; Wiley, KE; Isaacs, SD; Wu, Y; Liu, X; Zhang, N; Wang, C-H; Khandekar, J; Hulick, PJ; Shevrin, DH; Cooney, KA; Shen, Z; Partin, AW; Carter, HB; Carducci, MA; Eisenberger, MA; Denmeade, SR; McGuire, M; Walsh, PC; Helfand, BT; Brendler, CB; Ding, Q; Xu, J; Isaacs, WB

Published Date

  • May 2017

Published In

Volume / Issue

  • 71 / 5

Start / End Page

  • 740 - 747

PubMed ID

  • 27989354

Pubmed Central ID

  • PMC5535082

Electronic International Standard Serial Number (EISSN)

  • 1873-7560

Digital Object Identifier (DOI)

  • 10.1016/j.eururo.2016.11.033


  • eng

Conference Location

  • Switzerland